BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 21791472)

  • 21. Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse.
    Bachas C; Schuurhuis GJ; Reinhardt D; Creutzig U; Kwidama ZJ; Zwaan CM; van den Heuvel-Eibrink MM; De Bont ES; Elitzur S; Rizzari C; de Haas V; Zimmermann M; Cloos J; Kaspers GJ
    Br J Haematol; 2014 Sep; 166(6):902-10. PubMed ID: 24962064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
    Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Genetic prognostic factors in childhood acute myeloid leukemia].
    Reinhardt D; Von Neuhoff C; Sander A; Creutzig U
    Klin Padiatr; 2012 Oct; 224(6):372-6. PubMed ID: 22821298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
    Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations.
    Chou SC; Tang JL; Hou HA; Chou WC; Hu FC; Chen CY; Yao M; Ko BS; Huang SY; Tsay W; Chen YC; Tien HF
    Leuk Res; 2014 Nov; 38(11):1278-84. PubMed ID: 25260824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.
    Kuwatsuka Y; Tomizawa D; Kihara R; Nagata Y; Shiba N; Iijima-Yamashita Y; Shimada A; Deguchi T; Miyachi H; Tawa A; Taga T; Kinoshita A; Nakayama H; Kiyokawa N; Saito AM; Koh K; Goto H; Kosaka Y; Asou N; Ohtake S; Miyawaki S; Miyazaki Y; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kobayashi S; Kitamura K; Sakaida E; Ogawa S; Naoe T; Hayashi Y; Horibe K; Manabe A; Mizutani S; Adachi S; Kiyoi H
    Int J Hematol; 2018 Feb; 107(2):201-210. PubMed ID: 29027108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
    Grimwade D; Hills RK; Moorman AV; Walker H; Chatters S; Goldstone AH; Wheatley K; Harrison CJ; Burnett AK;
    Blood; 2010 Jul; 116(3):354-65. PubMed ID: 20385793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
    Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
    Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
    Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
    Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The frequency of NPM1 mutations in childhood acute myeloid leukemia.
    Braoudaki M; Papathanassiou C; Katsibardi K; Tourkadoni N; Karamolegou K; Tzortzatou-Stathopoulou F
    J Hematol Oncol; 2010 Oct; 3():41. PubMed ID: 20979630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.
    Zhu YM; Wang PP; Huang JY; Chen YS; Chen B; Dai YJ; Yan H; Hu Y; Cheng WY; Ma TT; Chen SJ; Shen Y
    J Transl Med; 2017 Aug; 15(1):178. PubMed ID: 28830460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.
    Hollink IH; Zwaan CM; Zimmermann M; Arentsen-Peters TC; Pieters R; Cloos J; Kaspers GJ; de Graaf SS; Harbott J; Creutzig U; Reinhardt D; van den Heuvel-Eibrink MM; Thiede C
    Leukemia; 2009 Feb; 23(2):262-70. PubMed ID: 19020547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.
    Dang H; Jiang A; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Jan; 44(1):55-61. PubMed ID: 22939316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
    Ho PA; Zeng R; Alonzo TA; Gerbing RB; Miller KL; Pollard JA; Stirewalt DL; Heerema NA; Raimondi SC; Hirsch B; Franklin JL; Lange B; Meshinchi S
    Blood; 2010 Aug; 116(5):702-10. PubMed ID: 20413658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.